Metoprolol Aurovitas (Metoprolol Tartrate)

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart, decreasing the response to adrenaline and noradrenaline. This leads to a slower heart rate, reduced contractile strength, and lower cardiac output, while also diminishing renin release from the kidneys, contributing to blood‑pressure reduction.

The appropriate dose of Metoprolol Aurovitas is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose on their own.

Safety data for Metoprolol Aurovitas in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metoprolol is a cardio‑selective (β1‑specific) blocker, which generally causes fewer respiratory side effects than non‑selective beta‑blockers. Compared with agents like atenolol, it has a shorter half‑life and may require twice‑daily dosing, but it offers similar efficacy for hypertension, angina, and heart‑failure management.

Metoprolol Aurovitas should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Metoprolol Aurovitas is taken orally, usually with or without food, as directed by a healthcare professional. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with asthma or COPD, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or signs of an allergic response.

Metoprolol Aurovitas is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and individuals in cardiogenic shock. Clinicians should also exercise caution in patients with uncontrolled asthma or severe peripheral vascular disease.